Intellia identifies genetic risk factor for liver complications in CRISPR trial

Data ReadoutNeutral

AI Analysis

Summary

Intellia Therapeutics identified a common genetic risk factor among patients who experienced elevated liver enzymes following treatment with its CRISPR gene editing therapy for ATTR amyloidosis.

Clinical Trial Data

Outcome Details

Identification of genetic risk factor for liver enzyme elevations

Importance:5/10

Sentiment:

0.10

CRISPRgene_editingsafetyliver_toxicityATTR_amyloidosis

Related Companies

$NTLA

Read the original article

Published by Endpoints News on August 6, 2026 3:33 PM

Read Original